Novel drug delivery systems for glaucoma

No Thumbnail Available

Links to Files

https://www.nature.com/articles/eye201182

Permanent Link

https://doi.org/10.1038/eye.2011.82
 http://hdl.handle.net/11603/21198

Collections

UMBC Chemical, Biochemical & Environmental Engineering Department

Author/Creator

Author/Creator ORCID

Date

2011-04-08

Type of Work

journal articles
Text

Department

Program

Citation of Original Publication

Lavik, E., Kuehn, M. & Kwon, Y. Novel drug delivery systems for glaucoma. Eye 25, 578–586 (2011). https://doi.org/10.1038/eye.2011.82

Rights

This item is likely protected under Title 17 of the U.S. Copyright Law. Unless on a Creative Commons license, for uses protected by Copyright Law, contact the copyright holder or the author.

Subjects

nanoparticle
PLGA
drug delivery
clinical trials
glaucoma

Abstract

Reduction of intraocular pressure (IOP) by pharmaceutical or surgical means has long been the standard treatment for glaucoma. A number of excellent drugs are available that are effective in reducing IOP. These drugs are typically applied as eye drops. However, patient adherence can be poor, thus reducing the clinical efficacy of the drugs. Several novel delivery systems designed to address the issue of adherence and to ensure consistent reduction of IOP are currently under development. These delivery systems include contact lenses-releasing glaucoma medications, injectables such as biodegradable micro- and nanoparticles, and surgically implanted systems. These new technologies are aimed at increasing clinical efficacy by offering multiple delivery options and are capable of managing IOP for several months. There is also a desire to have complementary neuroprotective approaches for those who continue to show progression, despite IOP reduction. Many potential neuroprotective agents are not suitable for traditional oral or drop formulations. Their potential is dependent on developing suitable delivery systems that can provide the drugs in a sustained, local manner to the retina and optic nerve. Drug delivery systems have the potential to improve patient adherence, reduce side effects, increase efficacy, and ultimately, preserve sight for glaucoma patients. In this review, we discuss benefits and limitations of the current systems of delivery and application, as well as those on the horizon.